Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Eli Lilly: A Safe Harbor Amid Market Volatility
Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...
Citi sees positive read-through to Lilly shares on FDA GLP-1 statement
Citi reiterated a Buy rating and $1,190 price target on Eli Lilly (LLY), saying the firm expects a positive read-through to the shares on FDA’s ...
FDA voices ‘concerns’ with unapproved GLP-1 drugs used for weight loss
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...
Zacks Investment Research on MSN9h
NVO vs. LLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novo Nordisk (NVO) and Eli Lilly (LLY). But which of these two stocks is more attractive to ...
Zacks Investment Research on MSN11h
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...
Investing Snacks15h
Proficio Capital Boosts Stake in Eli Lilly by 30%
Proficio Capital Partners LLC increased its holdings in Eli Lilly by 30.2% during Q4, acquiring an additional 1,562 shares. Proficio now owns 6,739 shares of Eli Lilly, valued at $5.2 million. Several ...